Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share price taken down

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on May 15, 2021 8:29am

179 Views

Post# 33209531

RE:RE:RE:RE:RE:RE:RE:Share price taken down

I think everyone agree need for nasdaq.

but not option now. Market cap lower than IPO, dilute shareholder over and over. Reverse split for nasdaq, then dilute by 30% and no longer qualify.

LosAngelesDave wrote: Webster defines backwater exchange - see TSX. You have 2 biotechs over 1b cap, Tril and Aup. Hence the backwater designation. Synonym - see janky, minor, wannabe, #wanttobeusa

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles